[Stitcher]

22.09.2008 | 14:26 Uhr
Axxonis Pharma AG, has identified and patented several new chemical entities as neuroprotective agents

http://www.presseportal.de/pm/71528/...onis_pharma_ag

Berlin (ots) - The new compounds will provide a "full time" protection of neurons against aging and degeneration. Continuous administration technologies, which are one of the core competencies of Axxonis Pharma AG, will additionally enable the concept of 24 hours protection. This is a completely new and innovative approach in radical scavenging therapy and in the therapy of neurological disorders induced by oxidative stress.

The new drugs in combination of non-invasive transdermal or minimal invasive (subcutaneous minipump) application methods will establish new potent neuroprotective therapies for patients suffering from Parkinson´s disease, Alzheimer´s disease, Huntington´s disease, Amyotrophic Lateral Sclerosis or Multiple System Atrophy or other neurological degenerative diseases induced by chemical radicals.

Axxonis Pharma AG has recently submitted Lisuride transdermal and subcutaneous drug products (Nenad®) for centralized EU procedure for continuous dopaminergic stimulation therapy of M. Parkinson and related disorders. Lisuride is known as a potent radical scavenger both in vitro and in vivo with strong antioxidant and neuroprotective effects in vulnerable CNS cell populations.

The new compounds which come from a joint research project, funded in part with financial means from the EU, between the Institute of Pharmacy (Prof. H.H. Pertz) of the Freie Universität Berlin, Germany, and Alfarma s.r.o., Cernosice, Czech Republic will extend significantly the portfolio of Axxonis Pharma AG and will substantiate long term growth.

tulip-garden2.gif

EMEA Application For Nenad(R) (lisuride) Transdermal Patch And Subcutaneous Infusion For Parkinson's And Restless Leg Syndrome

Article Date: 05 Jun 2008 - 4:00 PDT
http://www.medicalnewstoday.com/articles/110022.php

About Nenad(R)

Nenad(R) 10 cm squared and 20 cm squared transdermal patches, which release 2.5 microgram lisuride and 5.0 microgram lisuride per hour, respectively, have been developed as a new application form of the strong dopamine agonist lisuride in order to enhance efficacy and to improve tolerability. The Nenad(R) patch works by non-invasive transport of lisuride across the skin and provides continuous dopaminergic stimulation (CDS) over two days. For Parkinson's Disease, one or two 20 cm squared patches are applied every other evening; for RLS, one or two 10 cm squared patches are applied every other morning. With these schedules, only one up-titration step is required in Parkinson's Disease with a rapid onset of action (significant after only one week treatment) with a simultaneous reduction in early adverse events. In RLS, most patients respond satisfactorily to just one 10 cm squared patch or, in severe cases, two patches of 10 cm squared, with improvement also in day-time symptomatology.

Lisuride sc (Nenad(R) Powder for solution for sc infusion) was developed for the treatment of patients in an advanced stage of Parkinson's Disease. The continuous application of this parenteral dopamine agonist using a small portable minipump provides stable individual drug levels and thereby achieves superior therapeutic results in treatment-resistant stages of Parkinson's Disease complicated by motor fluctuations. Studies showed good therapeutic efficacy on "Off" (hypomobility) and "On" with troublesome dyskinesia (hypermobility).

Lisuride also has antifibrotic and antiproliferative effects as a strong antagonist of 5- HT (serotonin) 2B receptors and therefore is expected to cause no cardiac valvulopathy as is the case with some other dopamine agonists.

READ Medical News Today article from June